On December 19, the “Antibody Process ‘Intelligence’ Summit – From Lean to Excellence in Industrialization Practice” themed salon, hosted by Tofflon Life Sciences, was successfully held in Guangzhou. Dr. Qianhui Liang, Director of Cell Line and Upstream Process Development at Canton Biologics, was invited to attend and delivered a keynote speech titled “Technical Challenges and Response Strategies for High-Challenge Monoclonal Antibody Development: From Hard-to-Express Antibodies to Quality Regulation and Abnormal Characterization Analysis.”

Dr. Liang’s speech addressed industry pain points directly, systematically sharing Canton Biologics’ end-to-end solutions for tackling high-challenge antibody molecules, particularly “hard-to-express antibodies,” as they transition from laboratory development to commercial production. The presentation garnered widespread attention and sparked lively discussions among peers in attendance.

Into Deep Waters: When “Hard-to-Express Antibodies” Become Industrialization Bottlenecks

As biopharmaceutical R&D enters deeper waters, target innovation and molecular design are becoming increasingly complex. More and more antibody drugs exhibit “hard-to-express” characteristics at early stages — low expression levels, rampant aggregation, and fluctuating critical quality attributes. Dr. Liang pointed out that behind these issues lie the molecule’s inherent sequence deficiencies, poor heavy-light chain pairing, and the significant metabolic stress imposed on host cells. She emphasized that failing to identify and intervene in these risks during early development would create fatal bottlenecks for subsequent process scale-up and cost control.

Strategy 1: Design at the Source – “Defusing” the Molecule

Canton Biologics’ approach begins at the source. During the molecule screening and optimization phase, the team employs bioinformatics tools (such as IMGT/V-QUEST) to analyze germline gene pairing tendencies and optimize the distribution of hydrophobic and polar residues through rational design. This is akin to “defusing” potential sequence issues at the starting line, significantly reducing downstream development risks caused by inherent sequence flaws, thereby establishing a foundation for high expression and high quality from the very beginning.

Strategy 2: A Dedicated Platform – Transforming “Hard-to-Express” into “High-Yield”

For hard-to-express molecules already identified, Canton Biologics’ mature DTEasy™ Hard-to-Express Protein Platform becomes a key tool for tackling challenges. This platform integrates patented vectors, customized host cell lines, and efficient screening methods, functioning like a sophisticated “customized solution.” It has successfully stabilized the production of many complex proteins (such as special-structure antibodies and viral surface proteins) that were previously difficult for peers, achieving only milligram-level expression, to gram-per-liter high-yield levels, thereby overcoming the initial production capacity barrier for industrialization.

Strategy 3: Process Innovation – Achieving Precise Balance Between Yield and Quality



Achieving high expression is only the first step; maintaining stable, consistent quality under high-yield conditions is even more critical. Dr. Liang highlighted Canton Biologics’ CBoost™ Enhanced Process Platform. By employing technologies such as rocking motion bioreactors, it provides a low-shear, gentle environment for cells, significantly enhancing cell viability and protein yield. Simultaneously, to address challenges like high mannose glycan abnormalities that can arise from high yields, Canton Biologics has developed the capability for fine-tuning using process levers such as precisely adjusting pH and dynamically adding sugar precursors. This ensures product quality is firmly controlled while pursuing high yield.

Strategy 4: In-Depth Characterization – Solving Every Production “Puzzle”

True process mastery is demonstrated by a profound understanding of anomalies. Dr. Liang vividly illustrated Canton Biologics’ robust deep characterization and problem-tracing capabilities using the concrete example of a “pink-colored drug substance” observed during production. The team’s investigation pinpointed the cause to be a specific binding between vitamin B12 in the culture medium and the protein, and subsequently developed an effective process control strategy. This ability to see the subtle, conduct scientific root-cause analysis, and take action is the solid foundation for ensuring product safety, compliance, and stability.

Empowering Innovation: Canton Biologics’ One-Stop Industrialization Engine

The deep insights shared during this presentation stem from Canton Biologics’ extensive experience serving over 100 clients globally and supporting more than 30 IND projects. As an international biologics CDMO, Canton Biologics has established a powerful technology platform covering complex antibodies, vaccine multimers, and recombinant proteins, offering end-to-end solutions from gene sequence to commercial production. The company is committed to leveraging its reliable, efficient, and innovative core technology platform to serve as the most dependable engine for partners to overcome industrialization challenges and accelerate the launch of innovative drugs.